Core Viewpoint - A class action lawsuit has been filed against DexCom, Inc. alleging securities fraud due to undisclosed material design changes to its G6 and G7 glucose monitoring devices, which posed health risks to users and increased regulatory scrutiny [3][4][5]. Summary by Sections Lawsuit Details - The lawsuit covers investors who purchased DexCom securities from July 26, 2024, to September 17, 2025, claiming that the company made misleading statements regarding the reliability and safety of its devices [3]. - Allegations include unauthorized design changes to the G6 and G7 devices, which made them less reliable and posed health risks to users [3]. Regulatory Issues - On March 7, 2025, DexCom received a warning letter from the FDA regarding manufacturing and quality management concerns, leading to a share price drop of approximately 9.15% [4]. - The FDA's warning letter, published on March 25, 2025, indicated that the G6 and G7 devices were "adulterated" due to modifications made without prior approval, causing inaccuracies that could endanger users [5]. Market Reactions - Following the FDA's warning, DexCom's share price fell by $1.77, or about 2.4%, on March 25, 2025 [5]. - On September 8, 2025, Oppenheimer downgraded DexCom's rating to "perform" from "outperform," citing concerns over the G7's accuracy, which resulted in a share price decline of approximately 3.1% [6]. - A report by Hunterbrook Media on September 18, 2025, revealed severe health risks associated with the G7 devices, leading to a significant share price drop of about 11% the following day [7].

Core Viewpoint - An amended securities class action lawsuit has been filed against CarMax, Inc., expanding the class period to include purchases made between June 20, 2025, and November 5, 2025, with a lead plaintiff deadline set for January 2, 2026 [1]. Allegations Against Defendants - The complaint alleges that during the class period, defendants made false or misleading statements and failed to disclose that CarMax's growth prospects were overstated, attributing earlier growth in the 2026 fiscal year to temporary factors related to customer behavior influenced by tariff speculation [2]. - It is claimed that the positive statements made by defendants regarding the company's business and prospects were materially misleading and lacked a reasonable basis throughout the relevant time [2]. Lead Plaintiff Process - Investors in CarMax have until January 2, 2026, to seek appointment as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or they may choose to remain absent from the class [3]. - The lead plaintiff will represent all class members in directing the litigation and is typically the investor or small group of investors with the largest financial interest [3]. Firm Background - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions in various courts and has a reputation for recovering billions for victims of corporate misconduct [4].

Core Viewpoint - The lawsuit against Inspire Medical Systems, Inc. alleges that the company made false statements regarding the demand and launch of its implantable medical device for obstructive sleep apnea, leading to significant investor losses [3][4]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of investors who purchased Inspire securities from August 6, 2024, to August 4, 2025, alleging misleading statements and failure to disclose poor demand and inventory issues [3]. - The lawsuit claims that Inspire Medical failed to complete essential tasks for a successful product launch, contrary to the company's assurances to investors [3]. Group 2: Impact of Company Disclosure - On August 4, 2025, Inspire disclosed that the launch of Inspire V was delayed due to incomplete training and onboarding at treatment centers, which affected the ability to bill for procedures [4]. - The company admitted to poor demand for Inspire V, resulting in a reduction of its 2025 earnings guidance by over 80%, causing a significant drop in share price from $129.95 to $87.91, a decline of approximately 32.35% [4].

Core Viewpoint - Senate Democrats are investigating Fiserv, Inc. due to concerns over the company's financial forecasts and the role of its former CEO Frank Bisignano, following a significant drop in share price after disappointing Q3 2025 results [1][2]. Financial Performance - Fiserv's Q3 2025 results were described as "abysmal," leading to a 47% decline in share price on October 29, 2025, which resulted in a loss of $32 billion in shareholder value in a single day [2][7]. - The company revised its organic revenue growth expectations down to 3.5%-4% from a previously higher forecast, and adjusted its EPS outlook to $8.50-$8.60 [5][6]. Legal and Regulatory Actions - A securities fraud class action has been filed against Fiserv, focusing on the accuracy of the company's statements regarding its business and growth prospects during the class period from July 23, 2025, to October 29, 2025 [3][4]. - Lawmakers are seeking information on Bisignano's involvement in financial forecasting and whether he misled investors about the company's financial health [2][6]. Management Changes - Following the poor financial results, Fiserv announced a leadership shakeup, including the departure of its CFO and changes to the board of directors, effective January 1, 2026 [5][6]. Investor Sentiment - The market reacted negatively to Fiserv's revised guidance and management's admission of overly optimistic assumptions, raising questions about the company's transparency and management effectiveness [6][7].

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com. The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member. According to the Co ...

Core Viewpoint - Stride, Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with claims of misleading statements and non-compliance with legal requirements during the class period from October 22, 2024, to October 28, 2025 [1][3]. Allegations - The lawsuit alleges that Stride inflated enrollment numbers by retaining "ghost students" and cut staffing costs by overloading teachers beyond statutory limits [3]. - Stride is accused of ignoring compliance requirements, including background checks and special education services, and suppressing whistleblowers who reported financial directives to delay hiring and deny services [3]. - A complaint from Gallup-McKinley County Schools Board of Education against Stride included allegations of fraud and deceptive practices, leading to a nearly 12% drop in Stride's stock price [4]. - Following a report of "poor customer experience," Stride estimated a loss of 10,000-15,000 enrollments, resulting in a more than 54% decline in stock price [5]. Legal Process - Investors who purchased Stride securities during the class period can seek appointment as lead plaintiff in the lawsuit, which allows them to act on behalf of other class members [6]. Company Background - Stride provides proprietary and third-party online curriculum, software systems, and educational services [2].

NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP reminds investors in Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”) securities that a securities class action has been filed on behalf of all investors who purchased shares between August 6, 2024 and August 4, 2025 (the “Class Period”). Investors have until January 5, 2026 to seek appointment as lead plaintiff. PLEASE CLICK HERE TO JOIN THE CASE AND SUBMIT CONTACT INFORMATION Allegations The complaint filed allege ...

Core Viewpoint - A class action lawsuit has been filed against WPP plc, alleging securities fraud that negatively impacted shareholders between February 27, 2025, and July 8, 2025 [2][3]. Group 1: Lawsuit Details - The lawsuit claims that WPP's management made overly positive statements while concealing material adverse facts about the company's media arm, which was struggling to cope with macroeconomic challenges and losing market share [3]. - On July 9, 2025, WPP issued a trading update indicating a deterioration in performance, attributing it to macroeconomic uncertainties and weaker new business, partly due to ongoing restructuring efforts [4]. Group 2: Stock Price Impact - Following the trading update, WPP's stock price fell from $35.82 per share on July 8, 2025, to $29.34 per share on July 9, 2025, marking a decline of approximately 18.1% in just one day [5]. Group 3: Legal Representation - Levi & Korsinsky LLP, a recognized securities litigation firm, is representing the shareholders in this class action, highlighting their extensive experience and success in similar cases [8].

Core Viewpoint - A class action securities lawsuit has been filed against CarMax, Inc. alleging securities fraud that affected shareholders between June 20, 2025, and September 24, 2025 [2]. Group 1: Lawsuit Details - The lawsuit claims that CarMax's management made false statements regarding the company's growth prospects, suggesting that the growth was a temporary benefit driven by customer speculation about tariffs [3]. - It is alleged that the statements made by the defendants about CarMax's business operations and future prospects were materially false and misleading, lacking a reasonable basis during the relevant time [3]. Group 2: Next Steps for Affected Shareholders - Shareholders who experienced losses in CarMax stock during the specified timeframe are encouraged to seek information about their rights to recovery, with no cost or obligation to participate [4]. Group 3: Legal Representation - Levi & Korsinsky LLP, a recognized securities litigation firm, has a strong track record in securing recoveries for shareholders and has been ranked among the top securities litigation firms in the United States for seven consecutive years [5].

Core Viewpoint - A class action securities lawsuit has been filed against Fluor Corporation, alleging securities fraud that negatively impacted shareholders between February 18, 2025, and July 31, 2025 [2]. Group 1: Lawsuit Details - The lawsuit claims that Fluor Corporation made false statements and concealed significant issues related to costs associated with infrastructure projects, including subcontractor design errors, price increases, and scheduling delays [3]. - It is alleged that these issues, along with reduced capital spending from customers and economic uncertainty, had a substantial negative impact on the company's business and financial results [3]. - The complaint further asserts that Fluor's financial guidance for FY 2025 was unreliable, overstating the effectiveness of its risk mitigation strategy and understating the impact of economic uncertainty [3]. Group 2: Next Steps for Affected Shareholders - Shareholders who suffered losses during the specified timeframe are encouraged to seek information about their rights to recovery, with no cost or obligation to participate [4]. Group 3: Legal Representation - Levi & Korsinsky LLP, a recognized securities litigation firm, has a strong track record in securing recoveries for shareholders and has been ranked among the top securities litigation firms in the United States [5].